Kandrozid

Candesartan Cilexetil, the active ingredient in Kandrozid, is an angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to lower high blood pressure and to manage heart failure in adult patients.

GNH USA supplies Kandrozid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Candesartan Cilexetil is an angiotensin II receptor blocker used to treat conditions related to the renin‑angiotensin system.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and cardiovascular events. Heart Failure: improves symptoms, decreases hospital admissions, and enhances survival in patients with reduced ejection fraction. Left Ventricular Dysfunction after Myocardial Infarction: helps prevent adverse cardiac remodeling and supports functional recovery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Upper respiratory tract infection - Diarrhea - Nasal congestion

Serious or Rare Side Effects: - Angioedema - Severe hyperkalemia - Acute renal impairment - Hepatic dysfunction - Symptomatic hypotension - Neutropenia

Patients should be monitored for safety and appropriate use. - Blood pressure monitoring: check regularly to ensure therapeutic effect and avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor for hyperkalemia, especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Potential drug interactions require careful management.

Major Interactions (Avoid): - ACE inhibitors: combined use may increase risk of hyperkalemia and renal dysfunction. - Aliskiren (in pregnancy): concurrent use is contraindicated due to enhanced adverse renal effects. - Potassium‑sparing diuretics or supplements: may cause dangerous elevations in serum potassium.

Moderate Interactions (Monitor Closely): - NSAIDs: can attenuate antihypertensive efficacy and affect renal function. - Lithium: may increase lithium concentrations, necessitating serum level monitoring. - Thiazide diuretics: may potentiate hypotensive effect, requiring dose adjustments.